Plasma biomarkers combined with UPDRS and MoCA for differential assessments of amnestic cognitive impairment (aMCI), Parkinson’s disease (PD+PDD) and dementia with Lewy body (DLB): A pilot study

There would be tremendous value for having biomarker panels as screening tools for the assessment of AD and PD pathologies. Technologies that increase the sensitivity and accuracy of the measurement of plasma Aβ42, total Tau (t‐Tau), phosphorylated Tau (P‐tau),) have emerged and there is interest in testing plasm alpha synuclein (α‐syn). The specific aim of the present study was to assess the accuracy of plasma Aβ42, total Tau (t‐Tau), and α‐syn combined with clinical measures in identifying mild cognitive impaired (MCI), PD/PDD, and DLB cases.